Healthcare
from24/7 Wall St.
1 day agoOne Rare Disease Biotech Posts 97% Margins but the Faster Growing Rival Just Turned Its First Profit
Two rare-disease biotechs show diverging trajectories: Corcept has slower growth with high margins but thin operating profit, while Amicus achieves faster growth and sustainable profitability.